Related Experiment Videos
[Results of clinical application of cefpiramide in pediatrics]
Insights
Cefpiramide (CPM) demonstrates favorable pharmacokinetics and a 90.9% efficacy rate in pediatric patients, primarily those with acute respiratory tract infections. This antibiotic shows promise as a safe and effective treatment option for children.
Area of Science:
- Pharmacology and Therapeutics
- Pediatric Infectious Diseases
Context:
- Cefpiramide (CPM) is an antibiotic evaluated for pediatric use.
- Acute respiratory tract infections are common in children.
- Understanding drug pharmacokinetics and efficacy is crucial for pediatric treatment.
Purpose:
- To assess the pharmacokinetic profile of cefpiramide (CPM) after intravenous administration in children.
- To evaluate the clinical efficacy and safety of CPM in treating pediatric infections, particularly acute respiratory tract infections.
Summary:
- Intravenous cefpiramide (CPM) administration in pediatric patients resulted in measurable blood levels over 12 hours, with half-lives of 3.0 and 5.8 hours.
- In a study of 22 pediatric patients with acute respiratory tract infections, CPM administered via injection or infusion achieved a 90.9% effective rate.
- Adverse effects were minimal, with only isolated instances of increased eosinophils and elevated GOT, suggesting a favorable safety profile.
Impact:
- Cefpiramide (CPM) is identified as a potentially useful antimicrobial agent for pediatric infections.
- The findings support the use of CPM in pediatric clinical practice for managing common infections.
- Further research may explore CPM's role in broader pediatric infectious disease management.
Abstract:
After the intravenous injection of cefpiramide (CPM) at a dose of 10 mg/kg to 2 children, the average blood levels of CPM were 77.7 micrograms/ml at 15 minutes, 64.6 micrograms/ml at 30 minutes, 41.9 micrograms/ml at 1 hour, 31.9 micrograms/ml at 2 hours, 10.7 micrograms/ml at 4 hours and 3.28 micrograms/ml at 12 hours. The half-lives were 3.0 hours and 5.8 hours. When CPM was given to 22 pediatric patients with mainly acute respiratory tract infection at doses of 20 approximately less than 50 mg/kg/day divided into 2 times by intravenous injection (12 cases) and drip-infusion (10 cases) for 2 approximately 3 days (10 cases) or 4 approximately 6 days (12 cases), the effective rate was 90.9%. No side effects were observed except slight increase of eosinophil in 1 case slight elevation of GOT in 1 case. It was concluded that CPM is a useful drug for the treatment of infection in pediatric field.